Market Size of Orthobiologics Industry
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 6.28 Billion |
| Market Size (2029) | USD 9.14 Billion |
| CAGR (2024 - 2029) | 6.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Orthobiologics Market Analysis
The Orthobiologics Market size is estimated at USD 6.28 billion in 2024, and is expected to reach USD 9.14 billion by 2029, growing at a CAGR of 6.30% during the forecast period (2024-2029).
The COVID-19 outbreak is an unprecedented health concern and has significantly impacted the orthobiologics market globally. According to a 2021 update by the National Safety Council (NSC) in America, the Consumer Product Safety Commission (CPSC) reported that during the first seven months of the COVID-19 pandemic, visits to emergency departments for consumer product-related injuries decreased by 24%. The highest decrease in injuries was sports-related injuries associated with track and field. Hockey, soccer, baseball, football, and basketball witnessed a more than 60% reduction from March through September 2020. Thus, the COVID-19-imposed lockdown impacted the orthobiologics market significantly. However, with a better screening process, the market is now opening up, which is increasing growth. For instance, in April 2022, an article published in the Europe PMC stated that after a year of maintaining 'non-COVID' hospital status for elective surgery, restrictions began to ease as the COVID-19 positivity rate dropped to 1.2% in Nassau County, New York on 1 May 2021. On 3 May 2021, on-site pre-surgical testing (PST) appointments resumed. Thus, the market is expected to grow in the future.
The major factors driving the growth of the orthobiologics market are increased incidence of sports injury, road accidents, osteoarthritis, and increasing adoption of minimally invasive surgeries. As per the 2020 statistics by the United Kingdom National Health Service, tennis elbow is a common condition affecting about 1-3% of the population, indicating about four to seven cases per 1000 every year. The high incidences of sports injuries boost the demand for orthobiologics for effective treatment, thus fueling the market.
The global increase in the number of geriatrics and obese people is likely to lead to consequences like greater incidences of osteoarthritis. Consequently, the geriatric population and population with obesity are at higher risk of musculoskeletal disorders. According to the World Health Organization (WHO), approximately 1.71 billion people had musculoskeletal conditions worldwide in 2021. Among musculoskeletal disorders, low back pain causes the highest burden, with a prevalence of 568 million people. According to the report published by Versus Arthritis stated that over 20 million people in the United Kingdom (around a third of the population) live with a musculoskeletal (MSK) condition, such as arthritis and low back pain. Overall, 21% of the UK population lived with illness and disability (YLD) and was associated with MSK conditions. Low back, neck pain, and osteoarthritis are the most common causes of pain and disability. The source stated that over 430,000 people have rheumatoid arthritis, around 12,000 children have juvenile idiopathic arthritis, 220,000 people have axial spondylarthritis, and around 100,000 people have psoriatic arthritis. Nearly 8.5 million people have osteoarthritis, 10 million have back pain, 1.7 to 2.8 million people have fibromyalgia, 3 million have osteoporosis, and around 500,000 fragility fractures occur yearly. Therefore, with the increase in musculoskeletal injuries, the demand for orthobiologics is expected to increase, driving the market growth.
Moreover, launching new products and strategic initiatives adopted by key market players is expected to boost the studied market growth. For instance, in April 2021, Ventris Medical launched Allocell AF, a next-generation osteoinductive fiber allograft. It enhances intra-operative handling and increases biological responsiveness at the defect site.
Thus, due to the factors such as increased incidence of injury, obese people, and product launches, the studied market is expected to grow significantly during the study period. However, the high cost of biologic-based treatments and preference for other alternatives is expected to hinder the market growth.
